Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/123475
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHortelão, Ana C.-
dc.contributor.authorPatiño, Tania-
dc.contributor.authorPérez Jiménez, Ariadna-
dc.contributor.authorBlanco, Ángel-
dc.contributor.authorSánchez Ordóñez, Samuel-
dc.date.accessioned2018-07-11T13:07:48Z-
dc.date.available2018-11-27T06:10:17Z-
dc.date.issued2017-11-27-
dc.identifier.urihttp://hdl.handle.net/2445/123475-
dc.description.abstractThe use of enzyme catalysis to power micro- and nanomotors exploiting biocompatible fuels has opened new ventures for biomedical applications such as the active transport and delivery of specific drugs to the site of interest. Here, urease-powered nanomotors (nanobots) for doxorubicin (Dox) anticancer drug loading, release, and efficient delivery to cells are presented. These mesoporous silica-based core-shell nanobots are able to self-propel in ionic media, as confirmed by optical tracking and dynamic light scattering analysis. A four-fold increase in drug release is achieved by nanobots after 6 h compared to their passive counterparts. Furthermore, the use of Dox-loaded nanobots presents an enhanced anticancer efficiency toward HeLa cells, which arises from a synergistic effect of the enhanced drug release and the ammonia produced at high concentrations of urea substrate. A higher content of Dox inside HeLa cells is detected after 1, 4, 6, and 24 h incubation with active nanobots compared to passive Dox-loaded nanoparticles. The improvement in drug delivery efficiency achieved by enzyme-powered nanobots may hold potential toward their use in future biomedical applications such as the substrate-triggered release of drugs in target locations.ca
dc.format.extent24 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoengca
dc.publisherWiley-
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/10.1002/adfm.201705086-
dc.relation.ispartofAdvanced Functional Materials, 2018, vol. 28, p. 1705086-
dc.relation.urihttp://dx.doi.org/10.1002/adfm.201705086-
dc.rights(c) Wiley, 2017-
dc.subject.classificationNanotecnologia-
dc.subject.classificationMedicaments antineoplàstics-
dc.subject.otherNanotechnology-
dc.subject.otherAntineoplastic agents-
dc.titleEnzyme-powered nanobots enhance anticancer drug deliveryca
dc.typeinfo:eu-repo/semantics/articleca
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/311529/EU//LT-NRBS-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
Publicacions de projectes de recerca finançats per la UE

Files in This Item:
File Description SizeFormat 
L21_2018_Advanced Functional Materials_28_1705086_OA.pdf2.11 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.